These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33610176)

  • 1. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
    Komiya I; Yamamoto A; Sunakawa S; Wakugami T
    Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
    Hirano T; Hayashi T; Sugita H; Tamasawa A; Goto S; Tomoyasu M; Yamamoto T; Ohara M; Terasaki M; Kushima H; Ito Y; Yamagishi SI; Mori Y
    J Diabetes Investig; 2023 Dec; 14(12):1401-1411. PubMed ID: 37647503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triglyceride/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients.
    Ouchi G; Komiya I; Taira S; Wakugami T; Ohya Y
    Lipids Health Dis; 2022 Jan; 21(1):4. PubMed ID: 34996463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C; Masuda D; Koseki M; Yamashita S
    Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.
    Yoshida M; Nakamura K; Miyoshi T; Yoshida M; Kondo M; Akazawa K; Kimura T; Ohtsuka H; Ohno Y; Miura D; Ito H
    Cardiovasc Diabetol; 2020 Sep; 19(1):149. PubMed ID: 32979918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Pradhan AD; Paynter NP; Everett BM; Glynn RJ; Amarenco P; Elam M; Ginsberg H; Hiatt WR; Ishibashi S; Koenig W; Nordestgaard BG; Fruchart JC; Libby P; Ridker PM
    Am Heart J; 2018 Dec; 206():80-93. PubMed ID: 30342298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
    Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.
    Guérin M; Le Goff W; Lassel TS; Van Tol A; Steiner G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2001 Feb; 21(2):282-8. PubMed ID: 11156866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.
    Hoshino T; Ishizuka K; Toi S; Seki M; Kitagawa K
    J Atheroscler Thromb; 2022 Jul; 29(7):1020-1030. PubMed ID: 34248089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
    Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
    Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia.
    Hida Y; Imamura T; Kinugawa K
    J Clin Med; 2023 Nov; 12(21):. PubMed ID: 37959379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
    Yamashita S; Okazaki M; Okada T; Masuda D; Yokote K; Arai H; Araki E; Ishibashi S
    J Atheroscler Thromb; 2021 Sep; 28(9):974-996. PubMed ID: 33536398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertriglyceridemic hyperapoB in type 2 diabetes.
    Sniderman AD; Lamarche B; Tilley J; Seccombe D; Frohlich J
    Diabetes Care; 2002 Mar; 25(3):579-82. PubMed ID: 11874951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
    Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors.
    Kusunoki M; Sakazaki T; Tsutsumi K; Miyata T; Oshida Y
    Endocr Metab Immune Disord Drug Targets; 2021; 21(5):919-924. PubMed ID: 32819242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
    Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.